Zobrazeno 1 - 10
of 272
pro vyhledávání: '"Egeler, R.M"'
Autor:
Calkoen, F.G.J., Vervat, C., van Pel, M., de Haas, V., Vijfhuizen, L.S., Eising, E., Kroes, W.G.M., 't Hoen, P.A.C., van den Heuvel-Eibrink, M.M., Egeler, R.M., van Tol, M.J.D., Ball, L.M.
Publikováno v:
In Stem Cell Research March 2015 14(2):198-210
Autor:
Anninga, J.K, van de Vijver, M.J, Cleton-Jansen, A.M, Kristel, P.M.P, Taminiau, A.H.M, Nooij, M, Egeler, R.M, Hogendoorn, P.C.W
Publikováno v:
In European Journal of Cancer 2004 40(7):963-970
Autor:
Schepers, S.A., Engelen, V.E., Haverman, L., Caron, H.N., Hoogerbrugge, P.M., Kaspers, G.J.L., Egeler, R.M., Grootenhuis, M.A.
Publikováno v:
Schepers, S A, Engelen, V E, Haverman, L, Caron, H N, Hoogerbrugge, P M, Kaspers, G J L, Egeler, R M & Grootenhuis, M A 2014, ' Patient Reported Outcomes in Pediatric Oncology Practice: Suggestions for Future Usage by Parents and Pediatric Oncologists ', Pediatric Blood and Cancer, vol. 61, no. 9, pp. 1707-1710 . https://doi.org/10.1002/pbc.25034
Pediatric Blood & Cancer, 61, 1707-10
Pediatric Blood & Cancer, 61, 9, pp. 1707-10
Pediatric blood & cancer, 61(9), 1707-1710. Wiley-Liss Inc.
Pediatric Blood & Cancer, 61(9), 1707-1710
Pediatric Blood and Cancer, 61(9), 1707-1710. Wiley-Liss Inc.
Pediatric Blood & Cancer, 61, 1707-10
Pediatric Blood & Cancer, 61, 9, pp. 1707-10
Pediatric blood & cancer, 61(9), 1707-1710. Wiley-Liss Inc.
Pediatric Blood & Cancer, 61(9), 1707-1710
Pediatric Blood and Cancer, 61(9), 1707-1710. Wiley-Liss Inc.
Item does not contain fulltext Several studies in adults have shown patient reported outcomes (PROs) to be effective in enhancing patient-physician communication and discussion of Health Related Quality of Life outcomes. Although less studied, positi
Background: Bone is the most common organ of involvement in patients with Langerhans cell histiocytosis (LCH), which is often painful and associated with significant morbidity from pathological fractures. Current first-line treatments include chemoth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::c39c3d032c83c097580f0fb9c578b01e
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3101032
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3101032
Autor:
Buddingh, E.P., Schilham, M.W., Eriaty, S., Ruslan, N., Berghuis, D., Szuhai, K., Suurmond, J., Taminiau, A.H.M., Gelderblom, H., Egeler, R.M., Serra, M., Hogendoorn, P.C.W., Lankester, A.C.
Publikováno v:
Cancer Immunology, Immunotherapy, 60(4), 575-586
Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy, 60(4), 575-86
Cancer Immunology, Immunotherapy
Cancer Immunology, Immunotherapy, 60(4), 575-86
High-grade osteosarcoma occurs predominantly in adolescents and young adults and has an overall survival rate of about 60%, despite chemotherapy and surgery. Therefore, novel treatment modalities are needed to prevent or treat recurrent disease. Natu
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Nierkens, S., Lankester, A.C., Egeler, R.M., Bader, P., Locatelli, F., Pulsipher, M.A., Bollard, C.M., Boelens, J.J., Westhafen Intercontinental Grp
Publikováno v:
Cytotherapy, 17(12), 1667. Informa Healthcare
Cytotherapy, 17(12), 1667-1674
Cytotherapy, 17(12), 1667-1674
Clinical trials aimed at improving results of hematopoietic cell transplantation (HCT) by adjuvant cell-based interventions in children have been limited by small numbers and pediatric-specific features. The need for a larger number of pediatric HCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fcf9928eb19160ab41759afd190067e
https://hdl.handle.net/10807/228568
https://hdl.handle.net/10807/228568
Autor:
Buddingh, E.P., Ruslan, S.E.N., Reijnders, C.M.A., Szuhai, K., Kuijjer, M.L., Roelofs, H., Hogendoorn, P.C.W., Egeler, R.M., Cleton-Jansen, A.M., Lankester, A.C.
Background: In vitro expanded mesenchymal stromal cells (MSCs) are increasingly used as experimental cellular therapy. However, there have been concerns regarding the safety of their use, particularly with regard to possible oncogenic transformation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______202::1344a0629bd8257ef54b9f4b63fb6750
https://hdl.handle.net/1887/3627667
https://hdl.handle.net/1887/3627667
Autor:
Steekelenburg, M. van, Weel-Sipman, M.H. van, Zwinderman, A.H., Hoogerbrugge, P.M., Vossen, J.M.J.J., Egeler, R.M.
Publikováno v:
Nederlands Tijdschrift voor Geneeskunde, 146, 1542-6
Nederlands Tijdschrift voor Geneeskunde, 146, 33, pp. 1542-6
Nederlands Tijdschrift voor Geneeskunde, 146, 33, pp. 1542-6
Item does not contain fulltext OBJECTIVE: To evaluate the results of 30 years of allogeneic HLA-identical bone marrow transplantation (BMT) as the treatment for children with acquired severe aplastic anaemia. DESIGN: Retrospective, descriptive. METHO
Autor:
Calkoen, F.G.J., Vervat, C., Hoen, P.A.C. 't, Heuvel-Eibrink, M.M. van den, Ball, L.M., Tol, M.J.D. van, Egeler, R.M.
Publikováno v:
Pediatric Blood & Cancer, 61, S110-S111
ResearcherID
ResearcherID
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c836593aebc2e9d2cafefa6b1ae8a8b6
http://hdl.handle.net/1887/104278
http://hdl.handle.net/1887/104278